University of Chile
uchile.clTotal trials
179
Active
22
Phase 3
12
Total enrollment
666,931
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Trace lithium dose plus treatment as usual | — | — | — | — | — | 1 | |
| High dose of remifentanil | — | — | — | — | — | 1 | |
| Medium dose of remifentanil | — | — | — | — | — | 1 |
Next readouts
- 2026-08-31
- 2029-11-01
Top conditions
- Pain, Postoperative8
- Depression7
- Obesity6
- Stroke6
- Periodontitis5
- Covid195
- Critical Illness5
- Analgesia5
Frequently asked questions about University of Chile
- How many clinical trials does University of Chile have on ClinicalTrials.gov?
- University of Chile is listed as the lead sponsor on 179 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Chile's trials are in Phase 3?
- 12 of University of Chile's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does University of Chile focus on?
- University of Chile's most-studied conditions on ClinicalTrials.gov are Pain, Postoperative, Depression, Obesity, Stroke, Periodontitis.
- When are University of Chile's next clinical trial readouts?
- University of Chile has 2 upcoming primary-completion readouts tracked here; the soonest is “Remifentanil Effect on Burst Suppression Ratio”, expected around 2026-08-31.